US20130345283A1 - Process for the preparation of rotigotine - Google Patents

Process for the preparation of rotigotine Download PDF

Info

Publication number
US20130345283A1
US20130345283A1 US13/948,667 US201313948667A US2013345283A1 US 20130345283 A1 US20130345283 A1 US 20130345283A1 US 201313948667 A US201313948667 A US 201313948667A US 2013345283 A1 US2013345283 A1 US 2013345283A1
Authority
US
United States
Prior art keywords
rotigotine
preparation
dsc
amine
hydrobromide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/948,667
Inventor
Aldo Banfi
Gianluca Belogi
Claudio Fuganti
Roberta Pizzocaro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fidia Farmaceutici SpA
Original Assignee
Fidia Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia Farmaceutici SpA filed Critical Fidia Farmaceutici SpA
Priority to US13/948,667 priority Critical patent/US20130345283A1/en
Publication of US20130345283A1 publication Critical patent/US20130345283A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/08—Hydrogen atoms or radicals containing only hydrogen and carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/38—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Definitions

  • the present invention relates to 5,6,7,8-tetrahydro-6-S-[N-propyl-2-(2-thienyl)-N-ethyl]amino-1-naphthalenol, commonly known as Rotigotine (1), a medicament used in the therapy of the early stages of idiopathic Parkinson's disease, usually in the form of its hydrochloride salt.
  • the trimethylamine-borane complex is an expensive, flammable product; therefore, this method for linking the thienylacetic chain to the secondary nitrogen of 2 is industrially problematic, due to the known instability of boron hydrides at high temperatures.
  • Transformation of 3 into Rotigotine which is reported in the patents cited above and consists in hydrolyzing the methyl ether to free the phenol group, is carried out by treatment with boron tribromide at low temperature ( ⁇ 30° C. to ⁇ 45° C.) in inert solvents. After completion of the reaction, the boron tribromide excess should be destroyed by addition of methanol, thereby forming trimethyl borate. This treatment is expensive, technically cumbersome and gives rise to polluting by-products.
  • Rotigotine When using 48% hydrobromic acid under reflux for the conversion of 3 into Rotigotine, which is an established procedure for hydrolyzing phenol ethers, Rotigotine is formed together with a considerable amount of 5,6,7,8-tetrahydro-6-S-[N-(2-thienyl)-ethyl]amino-1-methoxynaphthalene 4, namely the de-alkylation product of the amino nitrogen
  • Object of the present invention is a process for the preparation of Rotigotine 1 or a pharmaceutically acceptable salt thereof,
  • aprotic solvents selected from e.g. hydrocarbons, such as toluene, chlorinated solvents, such as methylene chloride or chloroform, esters, such as ethyl or butyl acetate and ethers, such as isopropyl and isobutyl ether, at temperatures ranging from 80 to 90° C., to afford Rotigotine 1;
  • Rotigotine 1 optional salification of Rotigotine 1 with a pharmaceutically acceptable acid, preferably hydrochloric acid.
  • the 2-thienylethyl chain is inserted at the nitrogen of 6 by reductive amination, using the 2-thienylacetic acid-sodium boron hydride complex in toluene.
  • an amine 2 with enantiomeric excess (ee) even lower than 0.94 is used as the starting product and the hydrobromide 5 is subsequently recrystallized to increase the enantiomeric purity.
  • the hydrobromide salt 5 is therefore particularly advantageous and is a further aspect of the invention.
  • Form A can be obtained taking up Rotigotine hydrochloride obtained by salification of Rotigotine with hydrochloric acid in about 10 ml of ethanol per gram of hydrochloride and heating under reflux; an equal volume of ethyl acetate is then added and the mixture is left cooling until crystallization.
  • Form A is characterized by following infrared, DSC and X-ray spectra:
  • Form B can be obtained taking up Form A in ethanol (approximately 10 ml of ethanol per gram of Form A), heating under reflux and adding an equal volume of hexane; Rotigotine hydrochloride Form B precipitates upon cooling the solution at room temperature.
  • this crystalline form is characterized by the following infrared, DSC and X-ray spectra:
  • These two crystalline forms are a further object of the invention and can be conveniently used for the preparation of pharmaceutical forms, in particular those intended for the therapy of Parkinson's disease.
  • Said pharmaceutical forms may be prepared with conventional techniques and excipients, according to what described, for example, in Remington's Pharmaceutical Sciences Handbook, XXI Ed. Mack Pub., N.Y., U.S.A.
  • FIG. 1 IR spectrum of Rotigotine hydrochloride Form A
  • FIG. 2 DSC of Rotigotine hydrochloride Form A
  • FIG. 3 X-ray spectrum of Rotigotine hydrochloride Form A
  • FIG. 4 IR spectrum of Rotigotine hydrochloride Form B
  • FIG. 5 DSC of Rotigotine hydrochloride Form B
  • FIG. 6 X-ray spectrum of Rotigotine hydrochloride Form B
  • 2-N-Propyl-5-methoxy tetraline base 2 (15 g) was reacted with 100 mL of 48% HBr under reflux for 5 hours with stirring under nitrogen atmosphere. After completion of the reaction, the mixture was cooled to 0° C. and, after one night, the precipitate, consisting of 2-N-propyl-5-hydroxy tetraline hydrobromide 5, was collected by filtration, after which it was washed on the filter with cold water to neutrality. After drying, 19 g of product was obtained, corresponding to a 91% yield.
  • 2-N-Propyl-5-hydroxy tetraline hydrobromide ( 19 g) was finely ground and suspended in 100 mL of water in the presence of 200 mL of dichloromethane. An excess of K 2 CO 3 (200 mL, 20% aqueous solution) was added under stirring, at a temperature of 5-10° C. The organic phase was separated and extraction was repeated twice, after that the organic phase was washed with aqueous saturated NaCl, dried over sodium sulfate, and evaporated to give an oily residue.
  • the basic aqueous phase containing 2-thienylacetic acid, was carefully acidified with 10% sulfuric acid at 0° C. and extracted three times with ethyl acetate. Evaporation of the organic extract allowed to recover about 40 g of 2-thienylacetic acid.
  • the toluene phase containing Rotigotine 1 was extracted three times with 200 mL of 3N HCl. Subsequently, the acidic solution was added with NaHCO 3 (5% aqueous) to pH 8, and then extracted three times with 200 mL of ethyl acetate. Evaporation of the organic extract and drying provided Rotigotine 1 (80%) as a colourless oil.
  • step 1 The oil obtained at step 1 was then dissolved in 100 mL of ethanol; the solution was added with 1.5 equivalents of 37% HCl (5.3 mL), then the solution was evaporated to dryness under reduced pressure.
  • step 2 The solid resulting from step 2 was taken up in ethanol (160 mL) and heated under reflux, then added with ethyl acetate (160 mL) and the solution was left to spontaneously cool at room temperature, until incipient crystallization. Filtration provided 10.5 g of Rotigotine hydrochloride Form A (70%).
  • Rotigotine hydrochloride Form A (10.5 g), prepared according to the process described in the above example, was dissolved in 100 mL of ethanol at the reflux temperature. The solution was cooled to about 60° C., then added with hexane (100 mL) and the resulting solution was left to cool at room temperature, until incipient crystallization; the resulting solid was filtered with suction, washed with hexane and dried at about 85° C. under vacuum, to give 9.9 g of Rotigotine hydrochloride Form B (94%).

Abstract

A process for the preparation of Rotigotine (1)
Figure US20130345283A1-20131226-C00001
and of pharmaceutically acceptable salts thereof, which comprises the reductive amination of an amine of formula 6 with the 2-thienylacetic acid-sodium boron hydride complex and which makes use of hydrobromide 5 as an intermediate
Figure US20130345283A1-20131226-C00002
The process is advantageous from the industrial point of view in that it allows to obtain Rotigotine with high enantiomeric purity starting from optically active 5,6,7, 8-tetrahydro-6-(S)-N-propylamino-1-methoxy-naphthalene (2), avoiding the use of dangerous reactives, the need for difficult chromatographic separation or the formation of by-products.
Furthermore, two novel crystalline forms are disclosed.

Description

  • This application is a divisional application of U.S. Ser. No. 13/120,682 filed on Jun. 13, 2011 which a U.S. national stage of PCT/IB2009/006934 filed on Sep. 24, 2009 which claims priority to and the benefit of Italian Application No. MI2008A1713 filed on Sep. 26, 2008, the contents of which are incorporated herein by reference in their entirety.
    • FIELD OF THE INVENTION
  • The present invention relates to 5,6,7,8-tetrahydro-6-S-[N-propyl-2-(2-thienyl)-N-ethyl]amino-1-naphthalenol, commonly known as Rotigotine (1), a medicament used in the therapy of the early stages of idiopathic Parkinson's disease, usually in the form of its hydrochloride salt.
  • Figure US20130345283A1-20131226-C00003
    • BACKGROUND OF THE INVENTION
  • The preparation and therapeutical uses of Rotigotine were first disclosed in U.S. Pat. No. 4,564,628 and U.S. Pat. No. 4,885,308. The product currently pharmaceutically used is the S enantiomeric form or its hydrochloride salt, the known syntheses of which involve 2-N-propyl-5-methoxy tetraline S enantiomer (2) as the key intermediate
  • Figure US20130345283A1-20131226-C00004
  • which is prepared by optical resolution of the racemate according to what described in U.S. Pat. No. 4,968,837.
  • Figure US20130345283A1-20131226-C00005
  • A number of procedures for the transformation of amine 2 into Rotigotine are disclosed. Among them, a procedure involves heating 2 in xylene with 2-thienylacetic acid and the trimethylamine-borane complex (U.S. Pat. No. 4,564,628 and Pharmaceutisch Weekblad Sci. Ed. 1985, 7, 208-211), which affords 5,6,7,8-tetrahydro-6-S-[N-propyl-2-(2-thienyl)-N-ethyl]amino-1-methoxynaphthalene 3.
  • The trimethylamine-borane complex is an expensive, flammable product; therefore, this method for linking the thienylacetic chain to the secondary nitrogen of 2 is industrially problematic, due to the known instability of boron hydrides at high temperatures.
  • Transformation of 3 into Rotigotine, which is reported in the patents cited above and consists in hydrolyzing the methyl ether to free the phenol group, is carried out by treatment with boron tribromide at low temperature (−30° C. to −45° C.) in inert solvents. After completion of the reaction, the boron tribromide excess should be destroyed by addition of methanol, thereby forming trimethyl borate. This treatment is expensive, technically cumbersome and gives rise to polluting by-products. When using 48% hydrobromic acid under reflux for the conversion of 3 into Rotigotine, which is an established procedure for hydrolyzing phenol ethers, Rotigotine is formed together with a considerable amount of 5,6,7,8-tetrahydro-6-S-[N-(2-thienyl)-ethyl]amino-1-methoxynaphthalene 4, namely the de-alkylation product of the amino nitrogen
  • Figure US20130345283A1-20131226-C00006
  • The structural similarity of 4 and Rotigotine makes the separation thereof through physical methods (crystallization and/or chromatography) exceedingly problematic.
  • It would therefore be useful to provide a process for the preparation of Rotigotine starting from the resolved amine 2 which is industrially more advantageous.
    • DISCLOSURE OF THE INVENTION
  • Object of the present invention is a process for the preparation of Rotigotine 1 or a pharmaceutically acceptable salt thereof,
  • comprising the following steps:
  • Figure US20130345283A1-20131226-C00007
  • a) demethylation of 5,6,7,8-tetrahydro-6-(S)-N-propylamino-1-methoxynaphthalene 2
  • Figure US20130345283A1-20131226-C00008
  • by refluxing in 48% HBr, to afford 2-N-propyl-5-hydroxy tetraline hydrobromide 5
  • Figure US20130345283A1-20131226-C00009
  • b) liberation of 2-N-propyl-5-hydroxy tetraline base 6
  • Figure US20130345283A1-20131226-C00010
  • c) reductive amination reaction between amine 6 and 2-thienylacetic acid-sodium boron hydride complex in aprotic solvents selected from e.g. hydrocarbons, such as toluene, chlorinated solvents, such as methylene chloride or chloroform, esters, such as ethyl or butyl acetate and ethers, such as isopropyl and isobutyl ether, at temperatures ranging from 80 to 90° C., to afford Rotigotine 1;
  • d) optional salification of Rotigotine 1 with a pharmaceutically acceptable acid, preferably hydrochloric acid.
  • Therefore, the process of the invention differs from those of the prior art that:
  • a. it proceeds through the phenol amine 6 and
  • b. the 2-thienylethyl chain is inserted at the nitrogen of 6 by reductive amination, using the 2-thienylacetic acid-sodium boron hydride complex in toluene.
  • According to a particular embodiment of the invention, an amine 2 with enantiomeric excess (ee) even lower than 0.94 is used as the starting product and the hydrobromide 5 is subsequently recrystallized to increase the enantiomeric purity.
  • In fact, de-O-methylation of 2 to give 5 takes place in high yields and it has been observed that, when using an amine 2 with enantiomeric excess (ee) of 0.94, the hydrobromide 5 obtained by precipitation at the end of the process has ee 0.98. Therefore, precipitation from the hydrobromic acid aqueous solution already involves after completion of the demethylation reaction such an increase in enantiomeric purity as to provide enantiomerically pure Rotigotine at the end of the synthesis process.
  • The hydrobromide salt 5 is therefore particularly advantageous and is a further aspect of the invention.
  • The introduction of the 2-thienylethyl chain at the secondary nitrogen of 6 using the preformed complex between sodium borohydride and 2-thienylacetic acid in toluene as the reagent is advantageous on an industrial scale, as sodium borohydride is much less expensive than the trimethylamine-borane complex; furthermore, the latter reagent requires the use of xylene under reflux, whereas toluene at 80-90° C. is sufficient when using sodium borohydride.
  • It has also been found that crystallization of Rotigotine hydrochloride from a mixture consisting of ethanol and ethyl acetate provides a crystalline form herein referred to as Form A, whereas crystallization of Rotigotine hydrochloride Form A from a mixture consisting of ethanol and hexane provides a crystalline form herein referred to as Form B, whose respective chemical-physical characterizations are reported in FIGS. 1-6 (DRX diffractograms, IR spectra and DSC scanning). In particular, Form A can be obtained taking up Rotigotine hydrochloride obtained by salification of Rotigotine with hydrochloric acid in about 10 ml of ethanol per gram of hydrochloride and heating under reflux; an equal volume of ethyl acetate is then added and the mixture is left cooling until crystallization. Form A is characterized by following infrared, DSC and X-ray spectra:
  • IR (cm−1): 3074; 2946; 2621; 1732; 1589; 1464; 1367; 1275; 1083; 1025; 963; 850; 771; 729.
  • DSC: onset temperature: 108.8° C.; peak temperature: 123.0° C.
  • X-ray spectrum (2θ): 7.1; 8.4; 9.8; 10.0; 13.2; 14.5; 14.8; 17.1; 17.8; 18.0; 18.8; 20.7; 22.9; 23.5; 25.4.
  • Form B can be obtained taking up Form A in ethanol (approximately 10 ml of ethanol per gram of Form A), heating under reflux and adding an equal volume of hexane; Rotigotine hydrochloride Form B precipitates upon cooling the solution at room temperature. On the other hand, this crystalline form is characterized by the following infrared, DSC and X-ray spectra:
  • IR (cm−1): 3058; 2966; 2633; 1588; 1464; 1436; 1347; 1275; 1207; 1161; 1086; 1049; 1027; 85; 950; 898; 850; 805; 772; 709.
  • DSC: onset temperature: 134.5° C.; peak temperature: 146.0° C.
  • X-ray spectrum (2θ): 6.9; 9.2; 9.3; 13.3; 14.8; 15.0; 17.6; 17.8; 19.2; 19.6; 20.8; 21.9; 23.2; 24.2; 24.6; 25.0.
  • These two crystalline forms are a further object of the invention and can be conveniently used for the preparation of pharmaceutical forms, in particular those intended for the therapy of Parkinson's disease. Said pharmaceutical forms may be prepared with conventional techniques and excipients, according to what described, for example, in Remington's Pharmaceutical Sciences Handbook, XXI Ed. Mack Pub., N.Y., U.S.A.
  • The invention will be now illustrated in greater detail in the experimental section.
    • DISCLOSURE OF THE FIGURES
  • FIG. 1: IR spectrum of Rotigotine hydrochloride Form A
  • FIG. 2: DSC of Rotigotine hydrochloride Form A
  • FIG. 3: X-ray spectrum of Rotigotine hydrochloride Form A
  • FIG. 4: IR spectrum of Rotigotine hydrochloride Form B
  • FIG. 5: DSC of Rotigotine hydrochloride Form B
  • FIG. 6: X-ray spectrum of Rotigotine hydrochloride Form B
    •  EXPERIMENTAL SECTION Example 1 Preparation of 2-N-propyl-5-hydroxy tetraline hydrobromide (5)
  • 2-N-Propyl-5-methoxy tetraline base 2 (15 g) was reacted with 100 mL of 48% HBr under reflux for 5 hours with stirring under nitrogen atmosphere. After completion of the reaction, the mixture was cooled to 0° C. and, after one night, the precipitate, consisting of 2-N-propyl-5-hydroxy tetraline hydrobromide 5, was collected by filtration, after which it was washed on the filter with cold water to neutrality. After drying, 19 g of product was obtained, corresponding to a 91% yield. Analysis with chiral HPLC of the enantiomeric composition of the amines recovered from the first precipitate and, respectively, from the solid obtained by evaporating mother liquors to dryness, proved that, starting from an amine 2 with ee 0.94, a crystal of 5 is obtained with ee higher than 0.98. On the other hand, the amine recovered from mother liquors has ee 0.86.
    • Example 2 Preparation of Rotigotine Hydrochloride (1) (Form A)
  • Step 1—Preparation of Rotigotine
  • 2-N-Propyl-5-hydroxy tetraline hydrobromide (5, 19 g) was finely ground and suspended in 100 mL of water in the presence of 200 mL of dichloromethane. An excess of K2CO3 (200 mL, 20% aqueous solution) was added under stirring, at a temperature of 5-10° C. The organic phase was separated and extraction was repeated twice, after that the organic phase was washed with aqueous saturated NaCl, dried over sodium sulfate, and evaporated to give an oily residue.
  • In another round-bottom flask, 56 g of 2-thienylacetic acid was dissolved in 125 mL of toluene. The solution was added with 4.8 g of sodium borohydride in small portions, so that temperature did not exceed 20-25° C. One hour after the end of the addition, 13.6 g of the free amine obtained from hydrobromide 5 was added. The resulting toluene solution was heated at 80-90° C. and kept under nitrogen in these conditions for about 8 hours. After completion of the reaction, the mixture was cooled and carefully added with ethanol to decompose the reaction complex, then poured in ice-water containing 10% sodium carbonate. The organic phase was separated, further extracted with 10% sodium carbonate solution, washed with NaCl saturated solution and evaporated to a residue under reduced pressure.
  • The basic aqueous phase, containing 2-thienylacetic acid, was carefully acidified with 10% sulfuric acid at 0° C. and extracted three times with ethyl acetate. Evaporation of the organic extract allowed to recover about 40 g of 2-thienylacetic acid.
  • The toluene phase containing Rotigotine 1 was extracted three times with 200 mL of 3N HCl. Subsequently, the acidic solution was added with NaHCO3 (5% aqueous) to pH 8, and then extracted three times with 200 mL of ethyl acetate. Evaporation of the organic extract and drying provided Rotigotine 1 (80%) as a colourless oil.
  • Step 2—Preparation of Rotigotine Hydrochloride
  • The oil obtained at step 1 was then dissolved in 100 mL of ethanol; the solution was added with 1.5 equivalents of 37% HCl (5.3 mL), then the solution was evaporated to dryness under reduced pressure.
  • Step 3—Preparation of Rotigotine Hydrochloride Form A
  • The solid resulting from step 2 was taken up in ethanol (160 mL) and heated under reflux, then added with ethyl acetate (160 mL) and the solution was left to spontaneously cool at room temperature, until incipient crystallization. Filtration provided 10.5 g of Rotigotine hydrochloride Form A (70%).
    • Example 3 Preparation of Rotigotine Hydrochloride (1) (Form B)
  • Rotigotine hydrochloride Form A (10.5 g), prepared according to the process described in the above example, was dissolved in 100 mL of ethanol at the reflux temperature. The solution was cooled to about 60° C., then added with hexane (100 mL) and the resulting solution was left to cool at room temperature, until incipient crystallization; the resulting solid was filtered with suction, washed with hexane and dried at about 85° C. under vacuum, to give 9.9 g of Rotigotine hydrochloride Form B (94%).

Claims (4)

1. Rotigotine hydrochloride crystalline Form A characterized by the following IR, DSC and XRD spectra:
IR (cm−1): 3074; 2946; 2621; 1732; 1589; 1464; 1367; 1275; 1083; 1025; 963; 850; 771; 729
DSC: onset temperature: 108.8° C.; peak temperature: 123.0° C.
X-ray spectrum (2θ): 7.1; 8.4; 9.8; 10.0; 13.2; 14.5; 14.8; 17.1; 17.8; 18.0; 18.8; 20.7; 22.9; 23.5; 25.4.
2. Rotigotine hydrochloride crystalline Form B, characterized by the following IR, DSC and XRD spectra:
IR (cm−1): 3058; 2966; 2633; 1588; 1464; 1436; 1347; 1275; 1207; 1161; 1086; 1049; 1027; 85; 950; 898; 850; 805; 772; 709.
DSC: onset temperature: 134.5° C.; peak temperature: 146.0° C.
X-ray spectrum (2θ): 6.9; 9.2; 9.3; 13.3; 14.8; 15.0; 17.6; 17.8; 19.2; 19.6; 20.8; 21.9; 23.2; 24.2; 24.6; 25.0.
3. Pharmaceutical compositions containing Rotigotine hydrochloride Form A according to claim 1 in admixture with pharmaceutically acceptable excipients and/or carriers.
4. Pharmaceutical compositions containing Rotigotine hydrochloride Form B according to claim 2 in admixture with pharmaceutically acceptable excipients and/or carriers.
US13/948,667 2008-09-26 2013-07-23 Process for the preparation of rotigotine Abandoned US20130345283A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/948,667 US20130345283A1 (en) 2008-09-26 2013-07-23 Process for the preparation of rotigotine

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ITMI2008A001713A IT1392387B1 (en) 2008-09-26 2008-09-26 PROCESS FOR ROTIGOTINE PREPARATION
ITM2008A1713 2008-09-26
US201113120682A 2011-06-13 2011-06-13
US13/948,667 US20130345283A1 (en) 2008-09-26 2013-07-23 Process for the preparation of rotigotine

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US201113120682A Division 2008-09-26 2011-06-13

Publications (1)

Publication Number Publication Date
US20130345283A1 true US20130345283A1 (en) 2013-12-26

Family

ID=40637856

Family Applications (3)

Application Number Title Priority Date Filing Date
US13/120,682 Active 2030-03-05 US8519160B2 (en) 2008-09-26 2009-09-24 Process for the preparation of rotigotine
US13/948,667 Abandoned US20130345283A1 (en) 2008-09-26 2013-07-23 Process for the preparation of rotigotine
US13/948,633 Abandoned US20130317255A1 (en) 2008-09-26 2013-07-23 Process for the preparation of rotigotine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US13/120,682 Active 2030-03-05 US8519160B2 (en) 2008-09-26 2009-09-24 Process for the preparation of rotigotine

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/948,633 Abandoned US20130317255A1 (en) 2008-09-26 2013-07-23 Process for the preparation of rotigotine

Country Status (5)

Country Link
US (3) US8519160B2 (en)
EP (1) EP2331494A1 (en)
CA (1) CA2738392C (en)
IT (1) IT1392387B1 (en)
WO (1) WO2010035111A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009052972A1 (en) 2009-11-12 2011-09-15 Lts Lohmann Therapie-Systeme Ag Process for preventing the crystallization of drugs in a polymer film
ITMI20111622A1 (en) * 2011-09-08 2013-03-09 Fidia Farmaceutici PROCESS FOR ROTIGOTINE PREPARATION
US10611749B2 (en) * 2018-02-15 2020-04-07 Solara Active Pharma Sciences Limited Process for preparation of Rotigotine and intermediates thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US456428A (en) * 1891-07-21 Elevator and conveyer
US4564628A (en) * 1983-01-03 1986-01-14 Nelson Research & Development Co. Substituted 2-aminotetralins
CA1338894C (en) * 1988-01-15 1997-02-04 John Francis De Bernardis Aminomethyl-chroman and thiochroman compounds as ó-2-adrenergic antagonists
SE9301732D0 (en) * 1993-05-18 1993-05-18 Haakan Wilhelm Wikstroem NEW CENTRALLY ACTING 5-, 6-, 7-, AND 8-SUBSTITUTED SULPHONE ESTERS OF N-MONOSUBSTITUTED 2-AMINOTETRALINS
US5382596A (en) * 1993-08-05 1995-01-17 Whitby Research, Inc. Substituted 2-aminotetralins
AR026505A1 (en) * 1999-11-23 2003-02-12 Aderis Pharmaceuticals Inc IMPROVED PROCESS FOR THE PREPARATION OF AMINOTETRALINES REPLACED WITH NITROGEN

Also Published As

Publication number Publication date
WO2010035111A1 (en) 2010-04-01
US20110230541A1 (en) 2011-09-22
EP2331494A1 (en) 2011-06-15
US20130317255A1 (en) 2013-11-28
CA2738392C (en) 2017-06-06
US8519160B2 (en) 2013-08-27
ITMI20081713A1 (en) 2010-03-27
IT1392387B1 (en) 2012-03-02
CA2738392A1 (en) 2010-04-01

Similar Documents

Publication Publication Date Title
EP1971592B1 (en) Improved synthesis and preparations of duloxetine salts
US8198485B2 (en) Resolution of 4,5-dimethoxy-1-(methylaminomenthyl)-benzocyclobutane
JPH09216857A (en) Production of antipode of o-demethyltramadol
US9776953B2 (en) Isolation and purification of 6-aminocaproic acid
US20130345283A1 (en) Process for the preparation of rotigotine
US8207356B2 (en) Method for the preparation of (S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine hydrochloride (duloxetine)
US8455678B2 (en) Process for the preparation of fesoterodine with low impurities content
EP2376470B1 (en) Process for the preparation of (6s)-(-)-5,6,7,8-tetrahydro-6-[propyl-(2-thienyl)ethyl]amino-1-naphthol (rotigotine)
US7842717B2 (en) DNT-maleate and methods of preparation thereof
US20130296608A1 (en) Novel stereospecific synthesis of (-) (2s, 3s)-1-dimethylamino-3-(3-methoxyphenyl)-2-methyl pentan-3-ol
US20140343322A1 (en) Process for preparing levomilnacipran hcl
US20070173541A1 (en) DNT-succinate and methods of preparation thereof
EP2739610B1 (en) Process for the manufacture of ivabradine and of intermediates of synthesis thereof
ITMI20111622A1 (en) PROCESS FOR ROTIGOTINE PREPARATION
US20080207923A1 (en) Pure DNT-maleate and methods of preparation thereof
WO2000050379A1 (en) Process for the preparation of (1r, 2s, 4r) -(-) -2 - (2 -dimethylaminoethoxy) -2 -phenyl -1,7,7 - trimethylbicyclo [2.2.1] heptane
US20070191471A1 (en) DNT-fumarate and methods of preparation thereof

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION